{"name":"89bio, Inc.","slug":"89bio-inc","ticker":"","exchange":"","domain":"","description":"89bio, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for the treatment of liver diseases. The company's lead candidate, BIO89-100, is currently in Phase 2 clinical trials.","hq":"","founded":0,"employees":"~50","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":345037000,"netIncome":-367079000,"cash":126060000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BIO89-100","genericName":"BIO89-100","slug":"bio89-100","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"BIO89-100","genericName":"BIO89-100","slug":"bio89-100","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPVVhyX3VjbDdrOGhXX0M5X1hFdldtaXFLUzkyUFoxYWo3cTAyR3ZFQjZfeVFZUGZJd090MHltUlRHbE12Qk9VTVF0bXlRc0FEQmNoZ3lHblRUekJFbWVZSmtUcDc0bzk0emplaGFvZDZMWW1HT0tybEZxb0JPeXg4RGwyMzZDaGp4TTA40gFYQVVfeXFMTklna2FxQVZ6dTdSN1VlcUo2VTh2U2o0UEV6M29DeWlRS2VFR1kzTzQzaU5tRzNQZ0NaYVFjM29IQ25XUlMyc2JicUdzUU92REtZWFRpdXFLUQ?oc=5","date":"2026-02-24","type":"pipeline","source":"Law360","summary":"Life Sciences Group Of The Year: Gibson Dunn - Law360","headline":"Life Sciences Group Of The Year: Gibson Dunn - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPMUFBZzdzTFh6MDlLRVJycVlmUEdIVUZmX1hCTlpPU0wzelNCM0lpVWE5NGUwbnhMX2h5cGI0ZWwxOGRBVzQ0RHNkd2p4QTE3MkF1ZE1ZNUE2bEVSblZ1Y0xUMUd6OFNYMmc5M18xY0tkQ09KTVdYVVBYdEJqVXgzenpfSnp4eTJJR0JEQ0VzZlBmVHFrOGRtNkRBb0IydmFFUmp4c21JSU01ZDRQM09GRXNhU2hPOEhId2FfUw?oc=5","date":"2025-10-02","type":"deal","source":"Fierce Biotech","summary":"After courting 14 pharmas, 89bio was left between a Roche and hard place in buyout talks - Fierce Biotech","headline":"After courting 14 pharmas, 89bio was left between a Roche and hard place in buyout talks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQRVV5V0VOWVY3OVNtaVl0eVV6ZTdyRXNsVVI2eEc5NU1KOHJXem1JTFAySklqQ3gyeWRtZnBaVXJYeDQ5UDZlejFZVG1rYlFvangyeW4xVEcwLURxLXF1ejlwOGNJS1o0WnhEd3BJekdrVkpTM1pzSDVYbkszbzFWMC1MMmxBMWtzVDcwM3JMcHBGN0xpNG1vcVRId2FmYzh0cVE?oc=5","date":"2025-10-01","type":"pipeline","source":"bizjournals.com","summary":"How a small Bay Area drug company landed a potential $3.5 billion acquisition despite pharma funding drought - bizjournals.com","headline":"How a small Bay Area drug company landed a potential $3.5 billion acquisition despite pharma funding drought","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNYUNxWjlHQ2x4YmJLOHUxSGdMbHhGMEJodUpDZVVQNlNtQmw1bFBLWmJjZHJHbFBuZW9sby1VTm1vQXhVczZhSDFkc2c3bTNTREhoeWNIRjFFandoUEstN1FPay1zUEpXSnhMMjlJOTk2Ui1XYzhJbk1OYmh0aXBPa0F4SWo0OGFKdExOWTFCbFFlaHlJMmtiZVd1YXlEc1JIbnlEZUNCalFsR1VqOHJOOE84Tjl6a1p6WFRVNGtFczVnVmQw?oc=5","date":"2025-09-18","type":"deal","source":"Reuters","summary":"Roche to acquire liver drug developer 89bio for up to $3.5 billion - Reuters","headline":"Roche to acquire liver drug developer 89bio for up to $3.5 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOWnVHa0I5bnluVnNTWXBiTHJjRkVOQi1FYUl2czhnWnNiNmdOR0xMRXh6cFNoamhiWWVtODY4TTJ1S3VodHJkYmxFbGRXMExRYmp6TjljSzlvT2R2eVlhaWM5d2F4dGxNM0d4Zlllbjk0Um5lXzZ1OXp5T3R1UnNnMnpBRDBfUGc0Nm9qSHljOA?oc=5","date":"2025-09-18","type":"deal","source":"Pharmaceutical Technology","summary":"Roche signs agreement to acquire 89bio in $2.4bn deal - Pharmaceutical Technology","headline":"Roche signs agreement to acquire 89bio in $2.4bn deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE50QVhOOXpIT2FlTF84UjBYZ050OWFLcG5MdzdCU0x0b2ttU2VaUjE0dWVyb2dJWE5jMVUzQmFzOHhNYTRTOUFwenUwMnZjeFI5NUMzUTJGWmFZcWoyYjhoalNhdUFfc3l6WGJSZFk4blpfa25mdzNTdzhGdw?oc=5","date":"2025-09-18","type":"deal","source":"Barron's","summary":"89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion. - Barron's","headline":"89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOV1l0NUR1ZlBTcGR2Nkp0NlFWVW5UeVJuS0hnNVRwYVlFMndRNXFRRWdIa2lmZV9FSGpXZUtENDRkOXg1RFhoR1JJNTVzaVR4bC1TeU41dFJrRmo2LWU2S1ZGc2hoZFFPazlianY4c1pMWGlmTFZGSkRuYVJBV1FWNHZyNGZ1V211MHNZNG9OQm9fUzd4c0Y3UFhPTTQ?oc=5","date":"2025-09-18","type":"deal","source":"BioPharma Dive","summary":"Roche dives into MASH with $2.4B deal for 89bio - BioPharma Dive","headline":"Roche dives into MASH with $2.4B deal for 89bio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPRTZZLWZKQ3RpLWZFakUwMTlxTkZOckNnbGJvZ2o5Y2JhLWppU2xHbDJ4TFpCMVdNWVJTRGZ4LUduSDFEc01ULWtfb3R3LXRvSm8xRkgyRmZSejhEcm81dnRma0sxbkEwdklIX3JIWXZ2OFVBYjJXcUxhV0FVdmF6Q0lja1RNVWt4WnZsQjVERkk1T09kLWU4aVpwamRfX18wVnpJaThfeUlPQmlqZVVHQQ?oc=5","date":"2025-09-18","type":"deal","source":"Bloomberg.com","summary":"Roche to Buy Biopharmceutical Firm 89bio in $3.5 Billion Deal - Bloomberg.com","headline":"Roche to Buy Biopharmceutical Firm 89bio in $3.5 Billion Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNdVQ2aUh2RjFPWjhlUHBPVFlvMmJpNjRwa0ozSGI4MHVFaVRGM1JVV05IcTRtWkpvS0pRUE03RXltX3p4QmVSTklRa2NzREZaNmpUUE5UMTdVbUttUGREM2VnLUl4UEdWM29ybk9QQk9iMWpiSVBvWHBXQlJHVmJxR2hJRVZUUy0yUHp0UmZVX0I0Nk96bUEyM00xdWxtSldHLVdGX1hMTHEzVUc0NlF1UHNtSjBFdXNCV0NEbGlRaUNnbjd1TkhkRw?oc=5","date":"2025-09-18","type":"pipeline","source":"Citeline News & Insights","summary":"Roche Makes Major MASH Bid, Offering $2.4bn For 89bio - Citeline News & Insights","headline":"Roche Makes Major MASH Bid, Offering $2.4bn For 89bio - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxOQlpBNXgtdnlfdUJ4S1dPcWcyejgtaFRHdzdDM3RsYm5EbmlUOElNeGRUMTZqaVFnSWEzcnJkUV9ZMDBRNFBXeVdBNXlzOHFzRE1LbXk1Y2tmSE8wR2xTYk9MQ3RWanpXNV9rSF9nV3FabUczYV9KeEFPZVJFSUwtZk1rcEFDa3lvNkVRYmV3ODIyYjZ1Y21oUkdUdFhwNTl3eWlmdjhRR3RPbUdwUjJYbExNaERUakM2aENNcjJ1V1dpZk1rZzJFVFM4WFpWYXJOX2tIQmlsR2VmMFNQVC0xVEdLbEpRak84VGJOQnRZbXo0YjlVZHh2R2hqWTIyMThkZTBPaXREMVVkRWNiRFkzdk5iTXEyeWV5RE1SZ3JWalBpU1Z5ck9UWW94a1hOMjRRaEE?oc=5","date":"2025-09-18","type":"deal","source":"GlobeNewswire","summary":"Roche enters into a definitive merger agreement to acquire - GlobeNewswire","headline":"Roche enters into a definitive merger agreement to acquire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE1NRzJSdS1KQUFHYVpDLTJ1TmVWY3pYeUE2cnpyenRfNU44RlVHTGp4RUp5bzBUQXNGTUJPUkI3UnpJVG04TUxYU29LYXhnVHZpZ09YaDRVd181VlpFZ3EwNTlIOHp3cnFq?oc=5","date":"2025-09-18","type":"deal","source":"CTech","summary":"Roche strikes $3.5 billion deal for U.S.-Israeli biotech 89bio - CTech","headline":"Roche strikes $3.5 billion deal for U.S.-Israeli biotech 89bio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPOVpiVkhlX3ViU290czY2RWFqaGxENnF4UU9QaXpvdndCUno5Z3NzQlBYdnZaaGpsTVZfdFpRWWo2NzJOYnEySEZTYlUxTjY2dDlvZGlxMVMzRWRMN2RHQjE1MGV5SnQ5al9NT3VYQkhTMDIwaGdnMVA2QUlkaTdDeDY0Z2I1ODl2bmlkRThqMlNQRkFUS0lfUkxCTjduX2FPbTJhclJXbWZhaEJNUno0cS1EY3g2bnBuYmc?oc=5","date":"2025-09-18","type":"deal","source":"Seeking Alpha","summary":"Roche’s 89bio Buyout: Building A Combo-Ready Metabolic Franchise Beyond GLP-1 Wars (RHHBY) - Seeking Alpha","headline":"Roche’s 89bio Buyout: Building A Combo-Ready Metabolic Franchise Beyond GLP-1 Wars (RHHBY)","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":345037000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-367079000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":126060000,"cashHistory":[],"totalAssets":478685000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}